Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 12, 2020
Daily News
June 12, 2020
- Opinion Reflected to Certain Degree for Comparator PMP Deduction Rule: FPMAJ
June 12, 2020
- Impact of Off-Year Drug Re-Pricing Should Be Limited: FPMAJ
June 12, 2020
- Eisai’s Akana Elected as New Chair of FPMAJ’s Drug Pricing Committee
June 12, 2020
- New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
June 12, 2020
- MHLW to Allow Blood Collection for Use of Blood in Drug R&D under Amended Blood Law
June 12, 2020
- Takeda to Divest 18 Non-Core Meds in Asia-Pacific to Celltrion for US$278 Million
June 12, 2020
- Ono/Seikagaku’s Novel Osteoarthritis Drug Delivers in Japan PIII for Knee Pain
June 12, 2020
- 100 mg Version of Vimpat IV Infusion Now Available in Japan: UCB
June 12, 2020
- Shonan iPark to Launch VC Consortium
June 12, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…